We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03227926
Recruitment Status : Completed
First Posted : July 24, 2017
Last Update Posted : August 25, 2022
Sponsor:
Information provided by (Responsible Party):
Fondazione del Piemonte per l'Oncologia

Tracking Information
First Submitted Date  ICMJE July 18, 2017
First Posted Date  ICMJE July 24, 2017
Last Update Posted Date August 25, 2022
Actual Study Start Date  ICMJE October 11, 2017
Actual Primary Completion Date November 6, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 22, 2022)
Overall response rate (ORR) to panitumumab according to RECIST v1.1. [ Time Frame: Tumor assessments every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
Main objective of the study is the evaluation of objective response rate according to RECIST 1.1 criteria
Original Primary Outcome Measures  ICMJE
 (submitted: July 21, 2017)
Overall response rate (ORR) to panitumumab according to RECIST v1.1. [ Time Frame: Tumor assessments every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 22, 2022)
  • Progression Free Survival [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
    PFS is defined as the time from first treatment to the time of disease progression
  • Overall Survival [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
    OS is defined as the length of time from the start of treatment to death from any cause
  • Toxicity according to CTCAE version 4.03. [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
    Toxicity will be assessed using the Common Toxicity Criteria for Adverse Events version 4.03 (CTCAE).
Original Secondary Outcome Measures  ICMJE
 (submitted: July 21, 2017)
  • Progression Free Survival [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
  • Overall Survival [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
  • Toxicity according to CTCAE version 4.03. [ Time Frame: every 2 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance
Official Title  ICMJE A Phase II Trial of Rechallenge With Panitumumab Driven by RAS Clonal-mediated Dynamic of Resistance
Brief Summary This is a hypothesis driven, open label, single-arm, multiple centers, Phase II trial. The trial has been designed to prove or disprove whether a rechallenge with panitumumab can achieve an objective response rate (ORR= CR+PR) of 30% or more in a population of RAS wild type mCRC patients selected on the basis of RAS extended clonal evolution in their plasma.
Detailed Description

Colorectal cancer (CRC) is the third most common cancer in the world and the second leading cause of cancer death in the United States and the European Union. In the last decade, substantial advances in the treatment of the metastatic disease (mCRC) have more than doubled overall survival (OS) from 12 months to 30 months due to the refinement of fluoropirimidine-based chemotherapy and the introduction of antiangiogenics and targeted therapies.

Pharmacologic blockade of the epithelial growth factor receptor (EGFR) with specific monoclonal antibodies, namely, cetuximab and panitumumab, represents the mainstay of tumour targeted therapy for mCRC in patients with tumors not harboring extended RAS pathway mutations (KRAS, NRAS, or BRAF). Such alterations, which constitutively activate typical EGFR downstream transducers, have been shown to trigger substitute survival pathways that bypass therapeutic blockade of EGFR signalling, thus abating the efficacy of anti-EGFR antibodies ("primary resistance"). Even when response to anti-EGFR therapy occurs in the context of appropriate molecular selection, acquired ("secondary") resistance inevitably arises in all cases. Our group has extensively studied this phenomenon and has shown that extended-RAS alterations are the principal culprit of anti EGFR acquired resistance, and that altered RAS clones decay upon anti-EGFR treatment withdrawal, while tumor cells regain sensitivity to anti EGFR treatment. We have also documented that ctDNA profiles of individuals who benefit from multiple challenges with anti-EGFR antibodies, exhibit pulsatile levels of mutant KRAS. Collectively, these results indicate that the CRC genome adapts dynamically to intermittent anti-EGFR drug schedules, and provide a molecular explanation for the efficacy of re-challenge therapies based on EGFR blockade. Our results also give experimental support to the empirical-based clinical benefit observed, following cetuximab or panitumumab rechallenge in two small series of originally KRAS exon 2 wild type mCRC patients.

We propose to assess the efficacy and safety of re-challenging with panitumumab RAS-extend wild type mCRC patients with ctDNA-confirmed secondary resistance to anti EGFR treatment, after progression on second or further lines chemotherapy. As proof-of-concept, patients will be blood monitored throughout their therapeutic itinerary for the presence of extended-RAS alterations and EGFR-ectodomain mutations by ctDNA determination (liquid biopsy). We also include in our ddPCR panel 7 different EGFR extracellular domain (ECD) mutations as they occur in 15-20% of patients who acquired resistance to anti-EGFR drugs.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the "molecular eligibility" of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared "molecularly eligible" for the Trial Phase.

Patients resulting "molecularly eligible" at the RML checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated in the Trial Phase with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason (See Section 9.2.3) whichever comes first.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
    Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
    Other Name: VECTIBIX
  • Diagnostic Test: Molecular Screening
    Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
    Other Name: RML Liquid Biopsies analysis
Study Arms  ICMJE
  • Experimental: Screening Phase
    Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the "molecular eligibility" of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared "molecularly eligible" for the Trial Phase.
    Intervention: Diagnostic Test: Molecular Screening
  • Experimental: Trial Phase
    Patients resulting "molecularly eligible" at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first.
    Intervention: Drug: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
Publications * Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 22, 2022)
32
Original Estimated Enrollment  ICMJE
 (submitted: July 21, 2017)
129
Actual Study Completion Date  ICMJE December 31, 2021
Actual Primary Completion Date November 6, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Histologically confirmed diagnosis of metastatic colorectal cancer;
  2. Age ≥ 18 years;
  3. Written informed consent;
  4. Documented WT RAS exons 2, 3 and 4 (KRas and NRas) and WT BRAF V600E for anti-EGFR treatment.
  5. Complete or partial response to anti EGFR antibodies in any line either received as monotherapy or in combination with chemotherapy;
  6. Imaging documented progression while on therapy with a therapeutic regimen including anti-EGFR mAb;
  7. Imaging documented progression at the last treatment regimen that must be anti-EGFR free;
  8. Patient must be RAS and EGFR ectodomain wild type in a liquid biopsy performed no longer that 4 weeks after progression to the last anti-EGFR free treatment
  9. FFPE sample used for eligibility to anti-EGFR prescription (see criteria 4) must be available for custom gene panel profiling (as described in appendix B). Otherwise if sample is not available, center must have already perfomed a genotyping on this tissue sample according to appendix B.
  10. ECOG performance status ≤ 2;
  11. At least one measurable tumor lesion as per RECIST v1.1. Lesions in previously irradiated areas or those that have received other loco-regional therapies (i.e. percutaneous ablation) should not be considered measurable unless there is clear documented evidence of progression of the lesion since therapy. Imaging must be performed maximum within 28 days prior to registration;
  12. Normal organ functions;
  13. Negative serum pregnancy test within 1 week prior to the first study dose in all women of childbearing potential;
  14. Subjects and their partners must be willing to avoid pregnancy during the trial. Male subjects with female partners of childbearing potential and female subjects of childbearing potential must, therefore, be willing to use adequate contraception;
  15. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

Exclusion Criteria

  1. History of severe infusion reactions to monoclonal antibodies cetuximab or panitumumab;
  2. Symptomatic or untreated leptomeningeal disease and symptomatic brain metastasis;
  3. Clinically significant cardiac disease including:

    1. congestive heart failure requiring treatment (NYHA grade ≥ 2), Left ventricular ejection fraction (LVEF) < 45% as determined by Multigated acquisition (MUGA) scan or echocardiogram;
    2. history or presence of clinically significant ventricular arrhythmias or atrial fibrillation;
    3. clinically significant resting bradycardia;
    4. unstable angina pectoris ≤ 3 months prior to starting study drug;
    5. acute myocardial infarction ≤ 3 months prior to starting study drug;
    6. QTcF > 480 msec;
  4. History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism;
  5. Patients with interstitial pneumonitis or pulmonary fibrosis;
  6. Abnormal organ or bone marrow functions defined as:

    1. Absolute neutrophil count < 1.5 x 10/L;
    2. hemoglobin < 9 g/dL;
    3. alkaline phosphatase > 2.5 x upper normal limit (ULN), if liver metastases > 5 x ULN;
    4. aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2.5 x ULN, if liver metastases > 5 x ULN;
    5. bilirubin > 1.5 x ULN, if liver metastases > 2 x ULN;
    6. serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 50 mL/min calculated according to Cockroft-Gault;
    7. Patients with platelet count <100 x 10^9/L
  7. Previous or concurrent second malignancy. Exceptions: adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to study entry; or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to study entry.
  8. Patients with positive serology for HIV, HBV, HCV.
  9. Patients with a history of severe or life threatening hypersensitivity to the active substance or to any of the excipients.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03227926
Other Study ID Numbers  ICMJE 013-IRCC-10IIS-16
2016-002597-12 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Fondazione del Piemonte per l'Oncologia
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Fondazione del Piemonte per l'Oncologia
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Salvatore Siena, MD Grande Ospedale Metropolitano Niguarda - Milano
Study Chair: Alberto Bardelli, MD Fondazione del Piemonte per l'Oncologia
Study Chair: Silvia Marsoni, MD Fondazione del Piemonte per l'Oncologia
PRS Account Fondazione del Piemonte per l'Oncologia
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP